Regeneron is buying Decibel Therapeutics and its hearing loss gene therapies for a modest $109 million, the companies announced Wednesday morning.
Regeneron and Decibel have been longtime collaborators in developing hearing loss gene therapies, with their first deal dating back to 2017. Decibel’s lead program, which is also its only program in the clinic, is a gene therapy for people with congenital hearing loss from mutations in the otoferlin gene, which results in defective signaling from sound-sensing hair cells in the ear to the brain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.